vs
Adagio Medical Holdings, Inc.（ADGM）与GLOBUS MEDICAL INC（GMED）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $-3.5M）
Adagio Medical Holdings, Inc.是一家医疗科技企业，专注于开发和商业化用于治疗包括房颤在内的各类心律失常病症的冷冻消融平台，产品面向电生理临床医师，核心市场覆盖北美及欧洲，致力于提升心律疾病患者的治疗安全性与效果。
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
ADGM vs GMED — 直观对比
营收规模更大
GMED
是对方的Infinity倍
$0
自由现金流更多
GMED
多$205.9M
$-3.5M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $826.4M |
| 净利润 | $-10.1M | $140.6M |
| 毛利率 | — | 68.4% |
| 营业利润率 | — | 20.5% |
| 净利率 | — | 17.0% |
| 营收同比 | — | 25.7% |
| 净利润同比 | -380.6% | 430.4% |
| 每股收益（稀释后） | $-0.66 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADGMGMED
| Q4 25 | — | $826.4M | ||
| Q3 25 | $0 | $769.0M | ||
| Q2 25 | — | $745.3M | ||
| Q1 25 | — | $598.1M | ||
| Q4 24 | — | $657.3M | ||
| Q3 24 | $132.0K | $625.7M | ||
| Q2 24 | $254.0K | $629.7M | ||
| Q1 24 | — | $606.7M |
净利润ADGMGMED
| Q4 25 | — | $140.6M | ||
| Q3 25 | $-10.1M | $119.0M | ||
| Q2 25 | — | $202.8M | ||
| Q1 25 | — | $75.5M | ||
| Q4 24 | — | $26.5M | ||
| Q3 24 | $3.6M | $51.8M | ||
| Q2 24 | $-5.7M | $31.8M | ||
| Q1 24 | — | $-7.1M |
毛利率ADGMGMED
| Q4 25 | — | 68.4% | ||
| Q3 25 | — | 67.2% | ||
| Q2 25 | — | 66.6% | ||
| Q1 25 | — | 67.3% | ||
| Q4 24 | — | 59.9% | ||
| Q3 24 | -213.6% | 56.8% | ||
| Q2 24 | -168.5% | 58.7% | ||
| Q1 24 | — | 60.2% |
营业利润率ADGMGMED
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 17.9% | ||
| Q2 25 | — | 10.2% | ||
| Q1 25 | — | 16.2% | ||
| Q4 24 | — | 9.2% | ||
| Q3 24 | -3352.3% | 7.7% | ||
| Q2 24 | -2621.7% | 7.9% | ||
| Q1 24 | — | 1.3% |
净利率ADGMGMED
| Q4 25 | — | 17.0% | ||
| Q3 25 | — | 15.5% | ||
| Q2 25 | — | 27.2% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | 2731.8% | 8.3% | ||
| Q2 24 | -2257.5% | 5.0% | ||
| Q1 24 | — | -1.2% |
每股收益（稀释后）ADGMGMED
| Q4 25 | — | $1.01 | ||
| Q3 25 | $-0.66 | $0.88 | ||
| Q2 25 | — | $1.49 | ||
| Q1 25 | — | $0.54 | ||
| Q4 24 | — | $0.19 | ||
| Q3 24 | $0.02 | $0.38 | ||
| Q2 24 | $-7.35 | $0.23 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.7M | $557.2M |
| 总债务越低越好 | $21.2M | — |
| 股东权益账面价值 | $-1.3M | $4.6B |
| 总资产 | $31.5M | $5.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ADGMGMED
| Q4 25 | — | $557.2M | ||
| Q3 25 | $4.7M | $18.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $890.1M | ||
| Q3 24 | $28.3M | $71.9M | ||
| Q2 24 | — | $82.5M | ||
| Q1 24 | — | $80.4M |
总债务ADGMGMED
| Q4 25 | — | — | ||
| Q3 25 | $21.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADGMGMED
| Q4 25 | — | $4.6B | ||
| Q3 25 | $-1.3M | $4.4B | ||
| Q2 25 | — | $4.3B | ||
| Q1 25 | — | $4.1B | ||
| Q4 24 | — | $4.2B | ||
| Q3 24 | $76.6M | $4.1B | ||
| Q2 24 | $-140.5M | $4.0B | ||
| Q1 24 | — | $3.9B |
总资产ADGMGMED
| Q4 25 | — | $5.3B | ||
| Q3 25 | $31.5M | $5.1B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $5.3B | ||
| Q3 24 | $107.2M | $5.1B | ||
| Q2 24 | $-140.5M | $5.0B | ||
| Q1 24 | — | $4.9B |
负债/权益比ADGMGMED
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.18× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.0M | $248.6M |
| 自由现金流经营现金流 - 资本支出 | $-3.5M | $202.4M |
| 自由现金流率自由现金流/营收 | — | 24.5% |
| 资本支出强度资本支出/营收 | — | 5.6% |
| 现金转化率经营现金流/净利润 | — | 1.77× |
| 过去12个月自由现金流最近4个季度 | — | $588.8M |
8季度趋势，按日历期对齐
经营现金流ADGMGMED
| Q4 25 | — | $248.6M | ||
| Q3 25 | $-3.0M | $249.7M | ||
| Q2 25 | — | $77.9M | ||
| Q1 25 | — | $177.3M | ||
| Q4 24 | — | $210.3M | ||
| Q3 24 | $-6.4M | $203.7M | ||
| Q2 24 | — | $54.3M | ||
| Q1 24 | — | $52.4M |
自由现金流ADGMGMED
| Q4 25 | — | $202.4M | ||
| Q3 25 | $-3.5M | $213.9M | ||
| Q2 25 | — | $31.3M | ||
| Q1 25 | — | $141.2M | ||
| Q4 24 | — | $193.2M | ||
| Q3 24 | $-6.9M | $161.7M | ||
| Q2 24 | — | $26.5M | ||
| Q1 24 | — | $23.8M |
自由现金流率ADGMGMED
| Q4 25 | — | 24.5% | ||
| Q3 25 | — | 27.8% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 23.6% | ||
| Q4 24 | — | 29.4% | ||
| Q3 24 | -5254.5% | 25.8% | ||
| Q2 24 | — | 4.2% | ||
| Q1 24 | — | 3.9% |
资本支出强度ADGMGMED
| Q4 25 | — | 5.6% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | 437.9% | 6.7% | ||
| Q2 24 | — | 4.4% | ||
| Q1 24 | — | 4.7% |
现金转化率ADGMGMED
| Q4 25 | — | 1.77× | ||
| Q3 25 | — | 2.10× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 2.35× | ||
| Q4 24 | — | 7.94× | ||
| Q3 24 | -1.76× | 3.93× | ||
| Q2 24 | — | 1.71× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADGM
暂无分部数据
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
